Numis Maintains UDG Healthcare PLC (LON:UDG)’s “Reduce” Rating; Last Week Clinigen Group Plc (LON:CLIN) Analysts

Clinigen Group Plc (LON:CLIN) Logo

Numis maintained their “Reduce” rating on UDG Healthcare PLC (LON:UDG)‘s stock in an analyst note issued to investors and clients on 17 May.

Among 6 analysts covering Clinigen Group (LON:CLIN), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clinigen Group had 74 analyst reports since July 29, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Clinigen Group Plc (LON:CLIN) on Wednesday, September 23 with “Buy” rating. The stock has “Buy” rating by Peel Hunt on Wednesday, September 28. As per Thursday, June 9, the company rating was maintained by Peel Hunt. The stock has “Buy” rating by N+1 Singer on Wednesday, November 29. Peel Hunt maintained Clinigen Group Plc (LON:CLIN) on Tuesday, October 27 with “Buy” rating. The firm has “Buy” rating by Peel Hunt given on Thursday, March 1. The stock of Clinigen Group Plc (LON:CLIN) earned “Buy” rating by Numis Securities on Friday, June 24. N+1 Singer maintained the shares of CLIN in report on Wednesday, July 29 with “Buy” rating. The stock of Clinigen Group Plc (LON:CLIN) earned “Buy” rating by Peel Hunt on Thursday, December 1. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 28. See Clinigen Group Plc (LON:CLIN) latest ratings:

04/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 Maintain
27/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 1220.00 New Target: GBX 1160.00 Reiteration
19/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1350.00 Maintain
01/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1350.00 Maintain
27/02/2018 Broker: Numis Securities Rating: Add Old Target: GBX 1208.00 New Target: GBX 1208.00 Maintain
27/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1350.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1350.00 Maintain
18/01/2018 Broker: Berenberg Rating: Buy Old Target: GBX 1200.00 New Target: GBX 1220.00 Upgrade
17/01/2018 Broker: N+1 Singer Rating: Buy Old Target: GBX 1225.00 New Target: GBX 1225.00 Maintain
17/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 1350.00 New Target: GBX 1350.00 Maintain

UDG Healthcare plc, together with its subsidiaries, provides clinical, commercial, communication, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and continental Europe. The company has market cap of 2.30 billion GBP. It operates through three divisions: Ashfield, Sharp, and Aquilant. It has a 32.17 P/E ratio. The Ashfield segment offers commercialization and clinical services for the pharmaceutical and healthcare industry that comprise supporting healthcare professionals and patients at various stages of the product life cycle, as well as provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies.

Among 12 analysts covering UDG Healthcare PLC (LON:UDG), 6 have Buy rating, 1 Sell and 5 Hold. Therefore 50% are positive. UDG Healthcare PLC has GBX 1100 highest and GBX 5.15 lowest target. GBX 869.60’s average target is -6.14% below currents GBX 926.5 stock price. UDG Healthcare PLC had 110 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of UDG Healthcare plc (LON:UDG) has “Hold” rating given on Wednesday, November 18 by Berenberg. The firm earned “Buy” rating on Friday, October 7 by Berenberg. The firm has “Outperform” rating by Davy Research given on Friday, January 29. Berenberg maintained the stock with “Hold” rating in Friday, June 23 report. As per Wednesday, April 4, the company rating was maintained by Peel Hunt. The stock has “Add” rating by Peel Hunt on Tuesday, October 31. Berenberg downgraded it to “Hold” rating and GBX 745 target in Monday, May 8 report. The firm has “Buy” rating given on Friday, January 20 by Cantor Fitzgerald. As per Tuesday, November 28, the company rating was maintained by N+1 Singer. The stock of UDG Healthcare plc (LON:UDG) earned “Buy” rating by Berenberg on Friday, June 3.

The stock increased 0.05% or GBX 0.5 during the last trading session, reaching GBX 926.5. About 122,682 shares traded. UDG Healthcare plc (LON:UDG) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock decreased 0.06% or GBX 0.5 during the last trading session, reaching GBX 865. About 12,479 shares traded. Clinigen Group Plc (LON:CLIN) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Clinigen Group plc operates as a specialty pharmaceutical and services firm in the United Kingdom, Europe, the United States, and internationally. The company has market cap of 1.06 billion GBP. The Company’s Clinigen Clinical Trial Services business supplies and manages commercial medical products, including comparator drugs, adjuvant drugs, and rescue therapies for patients in clinical trials, as well as provides value added services. It has a 77.23 P/E ratio. The companyÂ’s Idis Managed Access business is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.